Kurs
+2,25%
Likviditet
0,06 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-11 | 07:30 | Bokslutskommuniké 2025 |
2025-11-25 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-08-27 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-08 | N/A | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2025-05-07 | N/A | Årsstämma |
2025-05-07 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-02-12 | - | Bokslutskommuniké 2024 |
2024-10-30 | - | Kvartalsrapport 2024-Q3 |
2024-08-28 | - | Kvartalsrapport 2024-Q2 |
2024-05-10 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2024-05-08 | - | Årsstämma |
2024-05-08 | - | Kvartalsrapport 2024-Q1 |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-10-25 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-11 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2023-05-10 | - | Årsstämma |
2023-05-10 | - | Kvartalsrapport 2023-Q1 |
2023-02-15 | - | Bokslutskommuniké 2022 |
2022-10-26 | - | Kvartalsrapport 2022-Q3 |
2022-10-25 | - | Extra Bolagsstämma 2022 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2022-05-11 | - | Årsstämma |
2022-05-11 | - | Kvartalsrapport 2022-Q1 |
2022-02-16 | - | Bokslutskommuniké 2021 |
2021-10-27 | - | Kvartalsrapport 2021-Q3 |
2021-08-25 | - | Kvartalsrapport 2021-Q2 |
2021-07-21 | - | Extra Bolagsstämma 2021 |
2021-05-14 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2021-05-12 | - | Årsstämma |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-10-28 | - | Kvartalsrapport 2020-Q3 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-05-14 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2020-05-13 | - | Årsstämma |
2020-05-13 | - | Kvartalsrapport 2020-Q1 |
2020-02-19 | - | Bokslutskommuniké 2019 |
2019-10-23 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-16 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2019-05-15 | - | Årsstämma |
2019-05-15 | - | Kvartalsrapport 2019-Q1 |
2019-02-20 | - | Bokslutskommuniké 2018 |
2018-10-24 | - | Kvartalsrapport 2018-Q3 |
2018-08-15 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2018-05-16 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-07 | - | Bokslutskommuniké 2017 |
2018-02-06 | - | Extra Bolagsstämma 2017 |
2017-11-15 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-05-18 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2017-05-17 | - | Årsstämma |
2017-05-17 | - | Kvartalsrapport 2017-Q1 |
2017-02-22 | - | Bokslutskommuniké 2016 |
2016-12-02 | - | Extra Bolagsstämma 2016 |
2016-11-16 | - | Kvartalsrapport 2016-Q3 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-05-19 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2016-05-18 | - | Årsstämma |
2016-05-18 | - | Kvartalsrapport 2016-Q1 |
2016-02-24 | - | Bokslutskommuniké 2015 |
2015-11-18 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-21 | - | X-dag ordinarie utdelning SPRINT 0.00 SEK |
2015-05-20 | - | Årsstämma |
2015-02-26 | - | Bokslutskommuniké 2014 |
2014-11-14 | - | Kvartalsrapport 2014-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
In the spring of 2025, Sprint Bioscience will present the VPS34 program at two different conferences: NextGen Biomed 2025 in London, England and the Tumour Models Summit Nordics in Stockholm, Sweden.
The results presented at the NextGen Biomed 2025 conference by Oxford Global in London from March 12-14 demonstrate that inhibition of VPS34 in mice activates the immune system and enhances the treatment response to STING agonists. This discovery opens new possibilities for treatment combinations that could lead to improved therapeutic responses in immunotherapies that rely on the patient's own immune system, such as anti-PD-1/PD-L1 antibodies. The presentation is titled “Improving STING agonist in-vivo efficacy in mice by combination with VPS34 inhibitors.”
The presentation at the Tumour Models Summit Nordics in Stockholm from April 9-10 will focus on the tumor models used in the program. This presentation is titled “Using syngeneic models to understand the molecular pathways leading to improved STING therapy using VPS34 inhibitors.” At both conferences, Sprint Bioscience will be represented by Santiago Parpal, Principal Scientist, Tumor Biology & Therapeutics.
"We have shown that inhibition of VPS34 can enhance the effect of immune-activating checkpoint inhibitors and STING agonists, which is very promising. The need for improved treatment responses in immuno-oncology is significant, as the effectiveness varies between patients and often diminishes over time. By presenting our previously published results at scientific conferences, we spread the knowledge about our programs and strengthen our already established reputation," says Johan Emilsson, CEO of Sprint Bioscience.
For further information, kindly contact:
Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost:johan.emilsson@sprintbioscience.com
About Sprint Bioscience AB (publ)
Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website; www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.